Philadelphia-based FMC said the split follows a four-year effort to reshape its businesses. The company has done some buying and selling during that period, in 2013 alone acquiring the fish oil businesses of Norway's Trygg Pharma Group for $345 million while divesting its peroxygens business to the private equity firm One Equity Partners for $200 million.
Company chairman and CEO Pierre Brondeau called the split "a natural progression of our strategy," saying the two entities will both be stronger on their own.
"We believe that creating two companies, each with its own publicly listed equity, will enable the management of each company to pursue its own strategy," Brondeau said. "This will give each company greater focus on the success factors that are most important to its business and allow the adoption of a capital structure that is appropriate to its business profile."
Post-split Brondeau will lead the agriculture and healthcare business. The CEO of the minerals unit has not yet been named. The agriculture unit is expected to generate about $3.35 billion in annual sales, sourcing ingredients to food and pharmaceutical products, as well as crop protection products for farmers.
The minerals business should generate about $1 billion in annual sales, specializing on alkali chemicals including soda ash, used by the glass, chemical processing and detergent industries, as well as lithium, which is used in batteries and for medical applications. FMC said the minerals operation is expected to generate strong cash flow and should "have the financial flexibility to pursue select investment opportunities."